Loading
Total declarations
Company
▲ Purchases (9 ops.)
▼ Sales (0 ops.)
Latest filing published 29 May 2026 for MAAT PHARMA, €5,580. Read the official filing
Filing timeline
BuySaleHerve Affagard
Insider track record
Disclosed buys
9
Disclosed sells
0
Signal history
Closed purchases
Market purchases
9
Positive at T+90
44%
Median T+90
-0.2%
Based on 9 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -0.2%Entry €2.96 · Close at T+90 €2.96
- +75.8%Entry €4.14 · Close at T+90 €7.28
- +83.9%Entry €3.97 · Close at T+90 €7.30
- -39.2%Entry €8.00 · Close at T+365 €4.86
- +6.7%Entry €7.48 · Close at T+365 €7.98
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Herve Affagard: trading record in brief
This profile gathers the share dealings of Herve Affagard in Maat Pharma, where the filings describe the role as chief executive. In total, 11 filings cover trades dated from 28 October 2021 to 28 May 2026.
Every open-market trade on record is a purchase: 9 purchases worth €86k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Since January 2026: 1 purchase and no sales on the market.
In size, the median ticket on the buying side is €5,580. Of 9 purchases, 1 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. Looking at 9 purchases old enough to measure, the stock rose over the following 90 days in 44% of cases; the median change was -0.2%. These figures describe past trades and do not predict future prices.
The record was last updated on 29 May 2026 with an open-market purchase (€5,580) in Maat Pharma. The median gap between a trade and its publication by AMF is 8 days. The regulation allows three business days to notify a trade (MAR article 19). Source: insider filings from AMF. Past trades are no guide to future returns.
Companies and markets linked to Herve Affagard
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations11 total
2,000 shares@ €2.790.010% mcap3.5% of flowActionEuronext ParisISIN FR00126348222026DD1117103
Canonical exit: 26 Aug 2026 (T+90)
2,600 shares@ €3.485.6% of flowActionEuronext ParisISIN FR00126348222025DD1071415
Canonical exit: 16 Feb 2026 (T+90)
430 shares@ €3.480.9% of flowActionEuronext ParisISIN FR00126348222025DD1070840
Canonical exit: 16 Feb 2026 (T+90)
4,375 shares@ €8.0021.8% of flowActionEuronext ParisISIN FR00126348222024DD967653
Canonical exit: 15 Aug 2024 (T+90)
2,940 shares@ €5.109.3% of flowActionEuronext ParisISIN FR00126348222023DD944150
Canonical exit: 21 Mar 2024 (T+90)
500 shares@ €6.101.9% of flowActionEuronext ParisISIN FR00126348222023DD930462
Canonical exit: 26 Dec 2023 (T+90)
6,250 shares@ €8.0031.2% of flowActionEuronext ParisISIN FR00126348222023DD885951
300 shares@ €10.251.9% of flowActionEuronext ParisISIN FR00126348222022DD851054
Canonical exit: 4 Oct 2022 (T+90)
1,818 shares@ €13.5015.3% of flowActionEuronext ParisISIN FR00126348222021DD798423
405 shares@ €13.573.4% of flowActionEuronext ParisISIN FR00126348222021DD798428
Canonical exit: 13 Feb 2022 (T+90)
606 shares@ €13.505.1% of flowActionEuronext ParisISIN FR00126348222021DD798713
Canonical exit: 26 Jan 2022 (T+90)
11 of 11 declarations
